Diagnosis and Treatment of Acute HIV: A Stitch in Time?
Rajesh T. Gandhi, MD
Associate Professor of Medicine, Harvard University
Director of HIV Clinical Services and Education
Massachusetts General Hospital, Boston, MA
Videos of live meetings of PRN in NYC are owned and published by Physicians’ Research Network, Inc.
Copyright © 2014. All rights reserved.
Raj Gandhi is Associate Professor of Medicine at Harvard Medical School, and the Director of HIV Clinical Services and Education at Massachusetts General Hospital. He has been actively involved in HIV care and research since 1996. Dr. Gandhi is the site leader of the Massachusetts General Hospital AIDS Clinical Research Site in the Harvard/Miriam AIDS Clinical Trials Unit (ACTU) and a member of the AIDS Clinical Trials Group HIV-1 Reservoirs and Eradication Transformative Science Group. He is also the Director of the Harvard University Center for AIDS Research (CFAR) Clinical Core. Dr. Gandhi is the organizer of the HIV Online Provider Education (HOPE) program, which is an internet-based educational conference series for physicians caring for HIV-infected patients in resource-limited settings. He is also an Associate Editor of Journal Watch Infectious Diseases and Contributing Editor to Journal Watch HIV/AIDS Clinical Care. He is a scientific member of the Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. His research interests include clinical trials of immune-based therapies for HIV, HIV reservoirs, and HIV/viral hepatitis coinfections.
At the completion of this educational session, learners will:
- Recognize the best approach to diagnosing acute HIV, including a new testing algorithm.
- Understand the evidence supporting treatment of acute HIV, including its impact on HIV reservoirs and immune activation.
- Identify the benefits of diagnosis and treatment of acute HIV for prevention of new infections.
This PRN CME activity is funded in part by unrestricted educational grants from:
Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Merck & Co, and ViiV Healthcare.
